Skip to content

Neuroplasticity: all studies

Page 91 of 178: studies 901 to 910 of 1,772, newest first. Back to the neuroplasticity overview

Research

An astrocytic ensemble at vHip-NAc synapses modulates cognitive impairments induced by chronic tetrahydrocannabinol exposure.

Nature Communications December 9, 2025 Cristina Martín-Monteagudo, Javier Sánchez Romero, Julia Adams et al.

Cannabis is the most widely used illicit drug, particularly during adolescence. Its consumption disrupts glutamate homeostasis and synaptic plasticity in the nucleus accumbens (NAc). Here, we identify a functionally distinct accumbal astrocytic ensemble, associated with the ventral hippocampus-NAc (vHip→NAc) circuit, that is critical for tetrahydrocannabinol (THC)-induced synaptic and...

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety

General Hospital Psychiatry December 9, 2025 Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales et al. 4 citations

The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental health conditions, notably depression, loneliness, and existential distress. Traditional pharmacological treatments often exhibit limited efficacy and poor tolerability in older patients, primarily due to age-related physiological changes and the...

Therapeutic Efficacy and Neurobiological Mechanisms of Nitrous Oxide in Treatment-Resistant Depression

Journal of Pharma Insights and Research December 5, 2025 Syed Ansar, S. Ahmed, Aishvarya Baburao Ghayale et al.

Major Depressive Disorder (MDD), particularly its treatment-resistant form, represents a substantial burden on global public health, characterized by low remission rates with conventional monoaminergic pharmacotherapy. The paradigm shift toward glutamatergic modulation has identified the N-methyl-D-aspartate (NMDA) receptor as a critical target for rapid-acting antidepressants. Nitrous oxide...

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.

Therapeutic Advances in Psychopharmacology December 4, 2025 Charles Dodds, Rachelle Dawson, Alexander Lim et al. 3 citations

Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional treatments. Through the modulation of pathways involved in synaptic plasticity, psychedelic interventions are believed to enhance the mechanisms underlying...

Exploring the therapeutic potential of psychedelics in treating substance use disorders.

Molecular Psychiatry December 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al.

Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of...

Beyond the brain: a computational MRI-derived neurophysiological framework for robotic conscious capacity.

Neuroscience & Biobehavioral Reviews December 1, 2025 Álex Escolà-Gascón, Kenneth Drinkwater, Andrew Denovan et al.

Explaining when neural activity supports conscious processing remains an unresolved question in neuroscience. Current frameworks describe correlates of consciousness but rarely provide thresholds to predict its emergence or recovery. We introduce the Attribution Consciousness Index (ACI), a metric that estimates the generative potential of consciousness by balancing measures of dynamic...

DOI: 10.1016/j.neubiorev.2025.106430 (opens in new tab) Full text (opens in new tab) Anesthesia monitoring Attribution consciousness index Disorders of consciousness Generative artificial intelligence +1

Resilience and Brain Changes in Long-Term Ayahuasca Users: Insights From Psychometric and fMRI Pattern Recognition.

Journal of Magnetic Resonance Imaging December 1, 2025 Lucas Rego Ramos, Orlando Fernandes, Tiago Arruda Sanchez 1 citation

Ayahuasca is an Amazonian psychedelic brew that contains dimethyltryptamine (DMT) and beta carbolines. Prolonged use has shown changes in cognitive-behavioral tasks, and in humans, there is evidence of changes in cortical thickness and an increase in neuroplasticity factors that could lead to modifications in functional neural circuits. To investigate the long-term effects of Ayahuasca usage...

DOI: 10.1002/jmri.70063 (opens in new tab) Full text (opens in new tab) Ayahuasca Emotion regulation Machine learning Pattern recognition

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.

Cureus December 1, 2025 Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.

Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...

Sonic Genealogies and Mystical Memory: Tracing Jalāl al-Dīn al-Rūmī’s Epigenetic Influence on Indo-Islamic Musical Consciousness

Trabzon İlahiyat Dergisi November 30, 2025 İsmail Eraslan

This study examines the transmission of mystical memory in Islamic musical traditions by exploring how the intellectual and aesthetic legacy of Mawlānā Jalāl al-Dīn Rūmī (d. 672/1273) resonated across the Indo-Islamic cultural sphere through epigenetic and neuroaesthetic mechanisms. While previous scholarship has primarily emphasized Rûmî’s written works and spiritual influence, this article...

Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice.

Clinical Psychopharmacology and Neuroscience November 30, 2025 Alessandro Serretti 2 citations

Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Two rapid-acting therapeutic classes, NMDA receptor modulators (ketamine, esketamine) and neuroactive-steroid GABA-A positive allosteric modulators (brexanolone, zuranolone), offer complementary approaches to restore circuit function....

DOI: 10.9758/cpn.25.1349 (opens in new tab) Full text (opens in new tab) Antidepressive agents Depression, postpartum Neurosteroids